Clinical Trials Logo

Deleterious BRCA2 Gene Mutation clinical trials

View clinical trials related to Deleterious BRCA2 Gene Mutation.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02282345 Completed - Clinical trials for Invasive Breast Carcinoma

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

Start date: April 16, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects of talazoparib when given before standard therapy in treating patients with breast cancer that has spread to nearby healthy tissue and has a mutation in a breast cancer, early onset (BRCA) gene. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may be especially effective in patients with BRCA mutations. It is not yet known whether adding talazoparib before standard treatment is safe in treating patients with BRCA mutated breast cancer.